These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18305010)

  • 1. Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor.
    Ehlert FJ; Griffin MT
    J Pharmacol Exp Ther; 2008 Jun; 325(3):1039-60. PubMed ID: 18305010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
    Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
    Redka DS; Pisterzi LF; Wells JW
    Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
    Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
    Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor.
    Leppik RA; Miller RC; Eck M; Paquet JL
    Mol Pharmacol; 1994 May; 45(5):983-90. PubMed ID: 8190113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
    May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
    Avlani V; May LT; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.
    May LT; Lin Y; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors.
    Cembala TM; Forde SC; Appadu BL; Lambert DG
    Eur J Pharmacol; 2007 Aug; 569(1-2):37-40. PubMed ID: 17588565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
    Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
    Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
    Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
    Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors.
    Lanzafame A; Christopoulos A; Mitchelson F
    J Pharmacol Exp Ther; 1997 Jul; 282(1):278-85. PubMed ID: 9223565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors.
    Krejcí A; Tucek S
    Mol Pharmacol; 2001 Oct; 60(4):761-7. PubMed ID: 11562438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
    Elsinghorst PW; Cieslik JS; Mohr K; Tränkle C; Gütschow M
    J Med Chem; 2007 Nov; 50(23):5685-95. PubMed ID: 17944454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
    Grossmüller M; Antony J; Tränkle C; Holzgrabe U; Mohr K
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):267-76. PubMed ID: 16362429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.
    Matsui H; Lazareno S; Birdsall NJ
    Mol Pharmacol; 1995 Jan; 47(1):88-98. PubMed ID: 7838137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation by certain conserved aspartate residues of the allosteric interaction of gallamine at the m1 muscarinic receptor.
    Lee NH; Hu J; el-Fakahany EE
    J Pharmacol Exp Ther; 1992 Jul; 262(1):312-6. PubMed ID: 1625205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors.
    Tränkle C; Weyand O; Schröter A; Mohr K
    Mol Pharmacol; 1999 Nov; 56(5):962-5. PubMed ID: 10531401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.
    Sykes DA; Dowling MR; Charlton SJ
    Mol Pharmacol; 2009 Sep; 76(3):543-51. PubMed ID: 19498041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
    Machová E; Jakubík J; El-Fakahany EE; Dolezal V
    J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.